Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.24.1.1.u2
Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2024
Stockholders' Equity  
Summary of restricted stock award activity

Weighted Average

Number of

Grant Date Fair

    

Shares

    

Value  

Non-vested at December 31, 2023

1,316,120

$

6.88

Granted

2,704,000

1.99

Forfeited

(23,894)

6.28

Vested

(253,550)

7.72

Non-vested at March 31, 2024

3,742,676

$

3.30

Summary of restricted stock units activity

    

    

Weighted Average

Number of

Grant Date Fair

Shares

Value

Non-vested at December 31, 2023

 

615,884

$

2.77

Forfeited

(17,638)

2.25

Non-vested at March 31, 2024

 

598,246

$

2.78

Summary of stock option award activity

Weighted Average 

Remaining

Weighted Average 

 Contractual Life

    

Stock Options 

    

Exercise Price

    

(in years)

Outstanding as of December 31, 2023

127,000

$

8.88

8.60

Outstanding as of March 31, 2024

127,000

$

8.88

8.35

Vested and exercisable as of March 31, 2024

20,250

$

24.74

5.83

Summary of warrant activities

Weighted Average 

Remaining

Weighted Average 

Contractual Life

    

Warrants 

    

Exercise Price 

    

(in years)

Outstanding as of December 31, 2023

30,097,671

$

2.36

3.00

Granted

14,702,840

0.96

Exercised

(2,661,233)

Outstanding as of March 31, 2024

42,139,278

$

2.02

4.07

Summary of stock-based compensation expense

The following table summarizes stock-based compensation expense for the three months ended March 31, 2024 and 2023 ($ in thousands):

For the three months ended March 31, 

    

2024

    

2023

Research and development

$

490

$

390

General and administrative

 

220

579

Total stock-based compensation expense

$

709

$

969